Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division
May 06 2024 - 6:00AM
Today marks a pivotal development for Brains Bioceutical Corp
("Brains Bio"), as it significantly strengthens its Veterinary
Health Division. This enhancement is led by John Boshart, a
distinguished figure in animal health with profound experience from
his tenures at Pfizer Animal Health and Zoetis. His arrival
signifies a strategic consolidation of talent and expertise aimed
at redefining standards within the veterinary sector.
Brains Bio’s Animal Health Division is empowered by the unique
properties of its THC-free CBD API, which boasts an ultra-low
detection limit of 0.000006%. This EU-GMP Certified API is pivotal
in clinical and preclinical studies, including a Phase III Clinical
Trial, highlighting its potential for therapeutic applications in
veterinary medicine.
The CBD API is supported by rigorous regulatory credentials,
including ICH-Q7 compliance, an actively maintained EU Active
Substance Master File (ASMF), and a US Drug Master File (DMF) filed
with the FDA. These certifications ensure the highest standards of
quality and regulatory compliance essential for veterinary use.
The core of Brains Bio’s enhanced Veterinary Health Division
lies in its focused approach to pharmaceutical development,
specifically tailored to meet the nuanced needs of the animal
health sector. Recognizing the unique challenges and opportunities
in veterinary medicine, the division is dedicated to pioneering the
development of cannabinoid-based pharmaceuticals that offer
targeted, safe, and effective treatments for animals.
This strategic focus is driven by a deep understanding of the
physiological and medical requirements specific to different animal
species. Through rigorous research and development, combined with
stringent safety and efficacy testing, Brains Bio aims to deliver a
portfolio of advanced therapeutic solutions that will not only
improve health outcomes but also enhance the quality of life for
animals globally.
John Boshart's appointment as Vice President of Veterinary API
and Business Development, reflects Brains Bio's commitment to
leveraging extensive pharmaceutical expertise and cutting-edge
research to advance animal health care. The division will utilize
Brains Bio’s exclusive cannabinoid science combined with one of the
limited global licenses to manufacture cannabinoid products
specifically for veterinary use. This powerful combination of
scientific acumen and legal empowerment sets a robust foundation
for innovation in animal wellness and care.
Ricky Brar, CEO of Brains Bio, emphasized the strategic nature
of this development: "By enhancing our Veterinary Health Division,
we are not just expanding; we are redefining the role of innovative
solutions in the veterinary landscape. Under the seasoned
leadership of John Boshart and supported by our unmatched
scientific resources, we are poised to set new benchmarks in the
industry. This expansion represents a significant stride towards
our vision of making a global impact by providing groundbreaking
solutions to the critical health challenges facing animals
worldwide."
The expansion is well-timed, as the global veterinary care
market is experiencing rapid growth, driven by increased pet
ownership and greater emphasis on animal health and longevity.
According to a report by Grand View Research, the global animal
prescription market is projected to reach approximately $58 billion
by 2026. This projection underscores the vast potential and
critical need for innovative health solutions within this space.
Full details on the market projections can be found at: Grand View
Research Report on Global Veterinary Care Market.
John Boshart shares his vision for his new role: "Leading this
dynamic initiative at Brains Bio is an exhilarating opportunity to
apply both my industry experience and our company’s unique
capabilities toward advancing animal health care globally. Our
division is uniquely positioned to spearhead significant
developments in veterinary health, driven by a combination of
scientific excellence, robust licensing, and strategic
partnerships. The potential to transform how health care is
delivered to animals is tremendous, and I am committed to ensuring
we achieve substantial and meaningful impacts as well as robust
growth."
ABOUT BRAINS BIOCEUTICAL CORP.
Brains Bio is the leader in evidence-based and science-led
pioneer of natural plant-based health and wellness solutions.
Brains Bio is a leading manufacturer of the highest quality
natural and pure active pharmaceutical ingredients (APIs), with a
unique suite of licenses and registrations, and is strategically
positioned to take advantage of the complex regulatory environment,
securing its first mover and product quality advantage. Brains Bio
is diversified across the pharmaceutical, medical, and
nutraceutical sectors within the rapidly growing cannabinoid
market, resulting in a strong and unique value proposition.
Follow Brains Bio on Social:
Twitter: @BrainsBio, LinkedIn: @BrainsBio, Instagram:
@BrainsPure
For media inquiries, please contact:
media@brainsbio.com
For investor relations, please contact:
ir@brainsbio.com
brainsbio.com